WO2012064150A3 - 벤프로페린 유도체를 유효성분으로 함유하는 혈관신생-관련 질환의 예방 및 치료용 조성물 - Google Patents
벤프로페린 유도체를 유효성분으로 함유하는 혈관신생-관련 질환의 예방 및 치료용 조성물 Download PDFInfo
- Publication number
- WO2012064150A3 WO2012064150A3 PCT/KR2011/008625 KR2011008625W WO2012064150A3 WO 2012064150 A3 WO2012064150 A3 WO 2012064150A3 KR 2011008625 W KR2011008625 W KR 2011008625W WO 2012064150 A3 WO2012064150 A3 WO 2012064150A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preventing
- related diseases
- angiogenesis
- composition
- active ingredients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11839421.2A EP2638910B1 (en) | 2010-11-11 | 2011-11-11 | Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases |
JP2013538655A JP5878928B2 (ja) | 2010-11-11 | 2011-11-11 | ベンプロペリン誘導体を有効成分として含有する、血管新生関連疾患の予防及び治療用組成物 |
US13/891,837 US8716288B2 (en) | 2010-11-11 | 2013-05-10 | Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0112343 | 2010-11-11 | ||
KR20100112343 | 2010-11-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/891,837 Continuation-In-Part US8716288B2 (en) | 2010-11-11 | 2013-05-10 | Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012064150A2 WO2012064150A2 (ko) | 2012-05-18 |
WO2012064150A3 true WO2012064150A3 (ko) | 2012-09-07 |
Family
ID=46051454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/008625 WO2012064150A2 (ko) | 2010-11-11 | 2011-11-11 | 벤프로페린 유도체를 유효성분으로 함유하는 혈관신생-관련 질환의 예방 및 치료용 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8716288B2 (ko) |
EP (1) | EP2638910B1 (ko) |
JP (1) | JP5878928B2 (ko) |
KR (1) | KR101323728B1 (ko) |
WO (1) | WO2012064150A2 (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
CN103626722B (zh) * | 2012-08-27 | 2016-06-01 | 天津药物研究院 | 一氧化氮供体型降血糖化合物、其制备方法和用途 |
CN104784122A (zh) * | 2014-01-20 | 2015-07-22 | 广东东阳光药业有限公司 | 一种包含苯丙哌林的固体制剂 |
KR20160041746A (ko) * | 2014-10-07 | 2016-04-18 | 한국생명공학연구원 | (s)-(-)-벤프로페린을 포함하는 암 예방 또는 치료용 조성물 |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
JP7111390B2 (ja) * | 2018-05-04 | 2022-08-02 | ブイエスファーマテック | 癌細胞の遊走及び浸潤抑制を介した癌転移抑制剤 |
CN108752290B (zh) * | 2018-06-27 | 2021-05-28 | 大连万福制药有限公司 | 一种绿色合成磷酸苯丙哌林中间体的方法 |
WO2021174475A1 (en) * | 2020-03-05 | 2021-09-10 | Givaudan Sa | Organic compounds |
KR102623917B1 (ko) * | 2021-07-16 | 2024-01-12 | 한국생명공학연구원 | 암 세포의 이동과 침윤 억제를 통한 암 전이 억제제 |
KR20230081285A (ko) | 2021-11-30 | 2023-06-07 | 주식회사 브이에스팜텍 | 고순도의 1-(1-(2-벤질페녹시)프로판-2-일)-2-메틸피페리딘 단일 이성질체의 제조방법 |
WO2023147852A1 (en) | 2022-02-02 | 2023-08-10 | Symrise Ag | Compositions (iii) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009018280A2 (en) * | 2007-07-30 | 2009-02-05 | Auspex Pharamaceuticals, Inc. | Substituted indoles |
US20090203763A1 (en) * | 2008-01-22 | 2009-08-13 | Auspex Pharmaceuticals, Inc. | Substituted benzhydrylethers |
US20100087455A1 (en) * | 2008-10-06 | 2010-04-08 | Auspex Pharmaceuticals, Inc. | Substituted xanthine compounds |
US20100226943A1 (en) * | 2004-02-17 | 2010-09-09 | University Of Florida | Surface topographies for non-toxic bioadhesion control |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8414098A (en) | 1997-08-19 | 1999-03-08 | Emory University | Noscapine derivatives, useful as anticancer agents |
WO2005121090A1 (en) * | 2004-06-02 | 2005-12-22 | Abbott Laboratories | Substituted piperidines that have antiangiogenic activity |
US20090325975A1 (en) * | 2005-07-15 | 2009-12-31 | Helmut H Buschmann | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
WO2007098939A1 (en) * | 2006-02-28 | 2007-09-07 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
US20090047336A1 (en) | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
PL2254579T3 (pl) * | 2008-02-18 | 2018-08-31 | Laboratorios Del. Dr. Esteve, S.A. | Zastosowanie związków wiążących się do ligandów receptora sigma do leczenia bólu neuropatycznego powstającego w konsekwencji chemioterapii |
-
2011
- 2011-11-11 WO PCT/KR2011/008625 patent/WO2012064150A2/ko active Application Filing
- 2011-11-11 KR KR1020110117634A patent/KR101323728B1/ko active IP Right Grant
- 2011-11-11 JP JP2013538655A patent/JP5878928B2/ja active Active
- 2011-11-11 EP EP11839421.2A patent/EP2638910B1/en active Active
-
2013
- 2013-05-10 US US13/891,837 patent/US8716288B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100226943A1 (en) * | 2004-02-17 | 2010-09-09 | University Of Florida | Surface topographies for non-toxic bioadhesion control |
WO2009018280A2 (en) * | 2007-07-30 | 2009-02-05 | Auspex Pharamaceuticals, Inc. | Substituted indoles |
US20090203763A1 (en) * | 2008-01-22 | 2009-08-13 | Auspex Pharmaceuticals, Inc. | Substituted benzhydrylethers |
US20100087455A1 (en) * | 2008-10-06 | 2010-04-08 | Auspex Pharmaceuticals, Inc. | Substituted xanthine compounds |
Also Published As
Publication number | Publication date |
---|---|
WO2012064150A2 (ko) | 2012-05-18 |
EP2638910B1 (en) | 2017-07-12 |
US8716288B2 (en) | 2014-05-06 |
EP2638910A4 (en) | 2014-04-16 |
JP5878928B2 (ja) | 2016-03-08 |
EP2638910A2 (en) | 2013-09-18 |
JP2013544815A (ja) | 2013-12-19 |
US20130245068A1 (en) | 2013-09-19 |
KR20120050918A (ko) | 2012-05-21 |
KR101323728B1 (ko) | 2013-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012064150A3 (ko) | 벤프로페린 유도체를 유효성분으로 함유하는 혈관신생-관련 질환의 예방 및 치료용 조성물 | |
MY197785A (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
EA201391315A1 (ru) | Гуанидиновое соединение | |
WO2013037479A8 (en) | Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
WO2011056021A3 (ko) | 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도 | |
MX2014010563A (es) | Benzodioxanos en combinacion con otros activos para inhibir la produccion de leucotrieno. | |
EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
WO2011159129A3 (ko) | 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 | |
WO2011141929A3 (en) | Aqueous pharmaceutical compositions of fluticasone and olopatadine | |
UA110013C2 (uk) | Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів | |
WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
CA2920410C (en) | Thienopiperidine derivative and use thereof | |
WO2011049327A3 (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
MX351059B (es) | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. | |
WO2011159137A3 (ko) | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 | |
WO2012161497A3 (ko) | 보습능이 우수한 펩타이드 유도체 및 이의 용도 | |
WO2010090494A3 (ko) | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 | |
PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
MD4563B1 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
BR112017014016A2 (pt) | método de redução da pressão intraocular, e, composição farmacêutica. | |
WO2014015137A3 (en) | Compositions and methods for treating dysproliferative diseases | |
WO2012134187A3 (ko) | 황반변성 예방 또는 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11839421 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2013538655 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011839421 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011839421 Country of ref document: EP |